FDAsafety guidance77% confidence
FDA AP — HYMPAVZI (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application BLA761369. Sponsor: PFIZER INC. Submission status: AP. Submission type: SUPPL. Review priority: PRIORITY. Active ingredients: MARSTACIMAB-HNCQ.
Supporting Context
- Therapeutic area
- Infectious Disease · Antibiotic
- Sub-indication
- General
Related signal: FDA Approves Supplemental Applications for ZYVOX by Pfizer